Sucralfate--alternative therapy for peptic-ulcer disease

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Peptic ulcer disease remains a significant gastrointestinal condition.
• Effective therapeutic agents are crucial for managing ulcers and improving patient outcomes.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, clinical efficacy, adverse reactions, and dosage of sucralfate.
• To evaluate sucralfate's role in peptic ulcer disease treatment.

Main Methods:

• Review of existing literature on sucralfate.
• Analysis of clinical studies comparing sucralfate with placebo, cimetidine, and antacids.

Main Results:

• Sucralfate forms a protective barrier at ulcer sites, neutralizing acid and inhibiting pepsin.
• Oral sucralfate shows 3-5% absorption with >90% fecal excretion.
• Effective for duodenal ulcers, comparable to cimetidine and antacids; less impressive for gastric ulcers.
• Few side effects reported, primarily constipation, xerostomia, and skin eruptions.

Conclusions:

• Sucralfate is a unique antiulcer drug with a favorable safety and efficacy profile.
• It is comparable to cimetidine and antacids for duodenal ulcer treatment.
• FDA-approved for short-term duodenal ulcer treatment.